To conclude, although glioma with FGFR3::TACC3 fusion is not a distinct tumor type in the WHO 2021 classification of CNS tumor, searching for FGFR3::TACC3 fusion in diffuse IDH-wildtype glioma especially if it displays an oligo-like appearance and whatever the age of the patient is of utmost importance since these tumors might benefit from targeted therapy, although the evidence for their efficacy remains limited to date. This evidence concerns the gene TACC3 and glioma.